GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch
A nationwide Danish registry study also found that GLP-1 agonist use was linked to a lower glaucoma risk. Compared to diabetic patients on other...
Deep research and expert guides on maintaining your visual health.
A nationwide Danish registry study also found that GLP-1 agonist use was linked to a lower glaucoma risk. Compared to diabetic patients on other...
Blind spots often develop gradually without symptoms. Start a free trial and take a quick visual field test to spot changes early.
Find Out NowGLP-1 receptor agonists are a class of medicines that copy the action of a natural hormone called glucagon-like peptide-1. They work by helping the body release more insulin when blood sugar is high, slowing how fast the stomach empties, and reducing appetite. These effects make them useful for treating type 2 diabetes and for helping some people lose weight. They are usually given by injection and, in a few cases, as a pill. Because they change how the body handles sugar and hunger, they can lead to meaningful improvements in blood sugar control and body weight. Common side effects include nausea, vomiting, diarrhea, and sometimes dizziness, especially when starting treatment. There are also rarer but more serious risks such as pancreatitis, gallbladder problems, and interactions with certain other diabetes medicines that can cause low blood sugar. People with certain medical histories, like some forms of thyroid cancer or specific hereditary conditions, may be advised not to use them. Overall, these medicines are important tools that require medical supervision to balance benefits and risks and to decide whether they are the right choice for a person.